Skip to main content
SpringerLink
Log in

Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Alternative tumor necrosis factor-α (TNF-α) inhibitors and non-TNF biologics are available as treatment options for rheumatoid arthritis patients who exhibit inadequate response to TNF-α inhibitor (TNF-IR patients). These agents have considerable efficacy compared with placebo, but head-to-head comparisons among these agents have not been performed. The objective of this study was to use Bayesian approach to compare the effectiveness of cycling TNF-α inhibitors versus switching to non-TNF biologics in TNF-IR patients. A systematic review was conducted using MEDLINE and Cochrane library. Key endpoints were the American College of Rheumatology (ACR) responses of 20/50/70 and the health assessment questionnaire (HAQ) score change at six months. Bayesian outcomes were calculated as the probability that OR is greater than one and HAQ score change difference is less than zero. Compared with TNF-α inhibitors, non-TNF biologics were associated with higher ACR response rates; in ACR20, the OR was 1.639 for abatacept [P(OR > 1) = 90.7 %], 1.871 for rituximab [P(OR > 1) = 96.2 %] and 3.52 for tocilizumab [P(OR > 1) = 99.9 %]. Similar trends were shown in the HAQ change comparison; the median differences (MD) were −0.259 for abatacept [P(MD < 0) = 100 %], −0.160 for rituximab [P(MD < 0) = 98.2 %], and −0.200 for tocilizumab [P(MD < 0) = 99.3 %]. In conclusion, switching to non-TNF biologics was more effective than cycling TNF-α inhibitor in TNF-IR patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • CADTH therapeutic review. 2010. Clinical and economic overview: biological response modifier agents for adults with rheumatoid arthritis. Canadian Agency for Drugs and Technologies in Health: Ottawa.

    Google Scholar 

  • Chatzidionysiou, K., and R.F. Van Vollenhoven. 2013. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scandinavian Journal of Rheumatology 42: 190–195.

    Article  CAS  PubMed  Google Scholar 

  • Cohen, S.B., P. Emery, M.W. Greenwald, M. Dougados, R.A. Furie, M.C. Genovese, E.C. Keystone, J.E. Loveless, G.R. Burmester, M.W. Cravets, E.W. Hessey, T. Shaw, and M.C. Totoritis. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism 54: 2793–2806.

    Article  CAS  PubMed  Google Scholar 

  • Devine, E.B., R. Alfonso-Cristancho, and S.D. Sullivan. 2011. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 31: 39–51.

    Article  CAS  PubMed  Google Scholar 

  • Dipiro, J.T., R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, and L.M. Posey. 2005. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill.

    Google Scholar 

  • Emery, P., E. Keystone, H.P. Tony, A. Cantagrel, R. Van Vollenhoven, A. Sanchez, E. Alecock, J. Lee, and J. Kremer. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 67: 1516–1523.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Genovese, M.C., J.-C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, C. Birbara, J. Box, K. Natarajan, I. Nuamah, T. Li, R. Aranda, D.T. Hagerty, and M. Dougados. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. New England Journal of Medicine 353: 1114–1123.

    Article  CAS  PubMed  Google Scholar 

  • Gomez-Reino, J.J., C. Rodriguez-Lozano, C. Campos-Fernandez, M. Montoro, M.A. Descalzo, and L. Carmona. 2012. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Annals of the Rheumatic Diseases 71: 382–385.

    Article  PubMed  Google Scholar 

  • Guyot, P., P.C. Taylor, R. Christensen, L. Pericleous, P. Drost, I. Eijgelshoven, G. Bergman, and M. Lebmeier. 2012. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom. Journal of Rheumatology 39: 1198–1206.

    Article  CAS  PubMed  Google Scholar 

  • Horton, S., M.H. Buch, and P. Emery. 2010. Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. Drug Healthcare and Patient Safety 2: 101–119.

    CAS  Google Scholar 

  • Jang, E.J., D.H. Kim, J. Ahn, B.H. Jang, and S.M. Choi. 2013. Methods for Bayesian meta-analysis. Seoul: National Evidence-based Healthcare Collaborating Agency.

    Google Scholar 

  • Jansen, J.P., B. Crawford, G. Bergman, and W. Stam. 2008. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 11: 956–964.

    Article  PubMed  Google Scholar 

  • Krishnan, E., T. Sokka, A. Hakkinen, H. Hubert, and P. Hannonen. 2004. Normative values for the health assessment questionnaire disability index: benchmarking disability in the general population. Arthritis and Rheumatism 50: 953–960.

    Article  PubMed  Google Scholar 

  • Launois, R., B. Avouac, F. Berenbaum, O. Blin, I. Bru, B. Fautrel, J.M. Joubert, J. Sibilia, and B. Combe. 2011. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. Journal of Rheumatology 38: 835–845.

    Article  CAS  PubMed  Google Scholar 

  • Lee, Y.H., J.H. Woo, Y.H. Rho, S.J. Choi, J.D. Ji, and G.G. Song. 2008. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatology International 28: 553–559.

    Article  CAS  PubMed  Google Scholar 

  • Lu, G., and A.E. Ades. 2004. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 23: 3105–3124.

    Article  CAS  PubMed  Google Scholar 

  • Miranda, L.C., H. Santos, J. Ferreira, P. Coelho, C. Silva, and J. Saraiva-Ribeiro. 2012. Finding rheumatoid arthritis impact on life (FRAIL Study): economic burden. Acta Reumatologica Portuguesa 37: 134–142.

    PubMed  Google Scholar 

  • Moran, J.L., P.L. Graham, S. Rockliff, and A.D. Bersten. 2010. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Critical Care 14: R134.

    Article  PubMed Central  PubMed  Google Scholar 

  • O’dell, J.R. 2004. Therapeutic strategies for rheumatoid arthritis. New England Journal of Medicine 350: 2591–2602.

    Article  PubMed  Google Scholar 

  • Odegård, S., A. Finset, T.K. Kvien, P. Mowinckel, and T. Uhlig. 2005. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scandinavian Journal of Rheumatology 34: 441–447.

    Article  PubMed  Google Scholar 

  • Orme, M.E., K.S. Macgilchrist, S. Mitchell, D. Spurden, and A. Bird. 2012. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 6: 429–464.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Ruderman, E.M. 2012. Overview of safety of non-biologic and biologic DMARDs. Rheumatology 51(Suppl 6): vi37–vi43.

    Article  PubMed  Google Scholar 

  • Salliot, C., A. Finckh, W. Katchamart, Y. Lu, Y. Sun, C. Bombardier, and E. Keystone. 2011. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Annals of the Rheumatic Diseases 70: 266–271.

    Article  CAS  PubMed  Google Scholar 

  • Schmitz, S., R. Adams, C.D. Walsh, M. Barry, and O. Fitzgerald. 2012. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Annals of the Rheumatic Diseases 71: 225–230.

    Article  CAS  PubMed  Google Scholar 

  • Singh, J.A., D.E. Furst, A. Bharat, J.R. Curtis, A.F. Kavanaugh, J.M. Kremer, L.W. Moreland, J. O’dell, K.L. Winthrop, T. Beukelman, S.L. Bridges Jr, W.W. Chatham, H.E. Paulus, M. Suarez-Almazor, C. Bombardier, M. Dougados, D. Khanna, C.M. King, A.L. Leong, E.L. Matteson, J.T. Schousboe, E. Moynihan, K.S. Kolba, A. Jain, E.R. Volkmann, H. Agrawal, S. Bae, A.S. Mudano, N.M. Patkar, and K.G. Saag. 2012. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research 64: 625–639.

    Article  CAS  Google Scholar 

  • Smith, H.S., A.R. Smith, and P. Seidner. 2011. Painful rheumatoid arthritis. Pain Physician 14: E427–E458.

    PubMed  Google Scholar 

  • Smolen, J.S., J. Kay, M.K. Doyle, R. Landewe, E.L. Matteson, J. Wollenhaupt, N. Gaylis, F.T. Murphy, J.S. Neal, Y. Zhou, S. Visvanathan, E.C. Hsia, and M.U. Rahman. 2009. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374: 210–221.

    Article  CAS  PubMed  Google Scholar 

  • Smolen, J.S., R. Landewe, F.C. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. De Wit, D. Aletaha, N. Betteridge, J.W. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J.M. Hazes, M. Kouloumas, T.K. Kvien, X. Mariette, K. Pavelka, P.L. Van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D.L. Scott, T. Sokka-Isler, J.B. Wong, and D. Van Der Heijde. 2013. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases. doi:10.1136/annrheumdis-2013-204573.

    Google Scholar 

  • Smolen, J.S., R. Landewe, F.C. Breedveld, M. Dougados, P. Emery, C. Gaujoux-Viala, S. Gorter, R. Knevel, J. Nam, M. Schoels, D. Aletaha, M. Buch, L. Gossec, T. Huizinga, J.W. Bijlsma, G. Burmester, B. Combe, M. Cutolo, C. Gabay, J. Gomez-Reino, M. Kouloumas, T.K. Kvien, E. Martin-Mola, I. Mcinnes, K. Pavelka, P. Van Riel, M. Scholte, D.L. Scott, T. Sokka, G. Valesini, R. Van Vollenhoven, K.L. Winthrop, J. Wong, A. Zink, and D. Van Der Heijde. 2010. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 69: 964–975.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Soliman, M.M., K.L. Hyrich, M. Lunt, K.D. Watson, D.P.M. Symmons, and D.M. Ashcroft. 2012. On Behalf of the British Society for Rheumatology Biologics, R. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care & Research 64: 1108–1115.

    CAS  Google Scholar 

  • Strand, V., G.R. Burmester, S. Ogale, J. Devenport, A. John, and P. Emery. 2012a. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology 51: 1860–1869.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Strand, V., V. Sharp, A.S. Koenig, G. Park, Y. Shi, B. Wang, D.J. Zack, and D. Fiorentino. 2012b. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Annals of the Rheumatic Diseases 71: 1143–1150.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Strand, V., and J.A. Singh. 2008. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. American Journal of Managed Care 14: 234–254.

    PubMed  Google Scholar 

  • Westhovens, R., J.C. Cole, T. Li, M. Martin, R. Maclean, P. Lin, B. Blaisdell, G.V. Wallenstein, R. Aranda, and Y. Sherrer. 2006. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology 45: 1238–1246.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea. (HI10C2020).

Conflict of interest

All authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. School of Pharmacy, Sungkyunkwan University, 300 Cheonchoen-dong, Jangan-gu, Suwon, Gyeonggi-do, 440-746, South Korea

    Hye-Lin Kim, Min-Young Lee, Sun-Young Park, Sun-Kyeong Park, Ji-Hye Byun, Sunhong Kwon & Eui-Kyung Lee

Authors
  1. Hye-Lin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min-Young Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sun-Young Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sun-Kyeong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ji-Hye Byun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sunhong Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eui-Kyung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eui-Kyung Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, HL., Lee, MY., Park, SY. et al. Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach. Arch. Pharm. Res. 37, 662–670 (2014). https://doi.org/10.1007/s12272-014-0337-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-014-0337-1

Keywords

Search

Navigation